

**LITERATUR****13.1 TERMINOLOGIE**

- Frost R, Steketee G (2002). *Cognitive Approaches to Obsessions and Compulsions: Theory, Assessment, and Treatment*. Amsterdam: Pergamon Elsevier Science.
- Hohagen F, Berger M (eds.) (1998). New perspectives in research and treatment of obsessive compulsive disorder. *Br J Psychiatry* 173 (Suppl 35): 1–96.
- Montgomery SA, Fineberg N, Montgomery D (1992). Phänomenologie und differenzialdiagnostischer Stellenwert der Zwangsstörung. In: Hand I, Goodman WK, Evers U (Hrsg.). *Zwangsstörungen. Neue Forschungsergebnisse*. Berlin, Heidelberg, New York: Springer, S. 15–23.
- Rasche-Räuchle H, Winkelmann G, Hohagen F (1995). Zwangsstörungen – Diagnose und Grundlagen. *Extr Psychiatr* 5: 22–31.
- Reinecker HS (1994). *Zwänge. Diagnose, Theorien und Behandlung*. Bern, Göttingen, Toronto: Huber.

**13.2 EPIDEMIOLOGIE UND VERLAUF**

- Bebbington PE (1998). The epidemiology of obsessive compulsive disorder. *Br J Psychiatry* 173 (Suppl 35): 2–6.
- Bijl RV, Ravelli A, van Zessen G (1998). Prevalence of psychiatric disorders in the general population: results of Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Soc Psychiatry Psychiatr Epidemiol* 33: 587–595.
- Degonda M, Wyss M, Angst J (1993). The Zurich Study. XVIII. Obsessive-compulsive disorders and syndromes in the general population. *Eur Arch Psychiatry Clin Neurosci* 243: 16–22.
- Jacobi F, Höfler M, Strehle J et al. (2014). Psychische Störungen in der Allgemeinbevölkerung: Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). *Nervenarzt* 85(1): 77–87.
- Kringlen E, Torgersen S, Cramer V (2002). A Norwegian psychiatric epidemiological study. *Am J Psychiatry* 158: 1091–1098.
- Rasmussen SA, Eisen JL (1992). The epidemiology and differential diagnosis of obsessive-compulsive disorder. In: Hand I, Goodman WK, Evers U (Hrsg.). *Zwangsstörungen. Neue Forschungsergebnisse*. Berlin, Heidelberg, New York: Springer, S. 1–14.
- Robins LN, Helzer JE, Weissman MM et al. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. *Arch Gen Psychiatry* 41: 317–322.

**13.3 SYMPTOMATIK UND TYPISIERUNG**

- Freeston MH, Rhéaume J, Ladouceur R (1996). Correcting faulty appraisals of obsessional thoughts. *Behav Res Ther* 34(5–6): 433–446.
- Freeston MH, Ladouceur R (1997). What do patients do with their obsessive thoughts? *Behav Res Ther* 35(4): 335–348.
- Winkelmann G, Rasche-Räuchle H, Hohagen F (1994). Zwangsstörung: Comorbidität und Implikation für die Behandlung. *Prax Klin Verhaltensmed Rehab* 25: 32–40.

**13.4 ÄTIOLOGIE UND PATHOGENESE**

- Brennan BP, Rauch SL, Jensen JE, Pope HG (2013). A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. *Biol Psychiatry* 73(1): 24–31.
- Fisher PL, Wells A (2005). Experimental modification of beliefs in obsessive-compulsive disorder: a test of the metacognitive model. *Behav Res Ther* 43(6): 821–829.
- Hollander E, Allen A, Steiner M, et al. (2003). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. *J Clin Psychiatry* 64(9): 1113–1121.
- Maina G, Albert U, Bogetto F (2001). Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. *Int Clin Psychopharmacol* 16(1): 33–38.

- Menzies L, Williams GB, Chamberlain SR, et al. (2008). White matter abnormalities in patients with obsessive-compulsive disorder and their first-degree relatives. *Am J Psychiatry* 165(10): 1308–1315.
- Milad MR, Rauch SL (2012). Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. *Trends Cogn Sci* 16(1): 43–51.
- Milad MR, Furtak SC, Greenberg JL, et al. (2013). Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. *JAMA Psychiatry* 70(6): 608–618.
- Salkovskis PM, Forrester E, Richards C (1998). Cognitive-behavioral approach to understanding obsessional thinking. *Br J Psychiatry Suppl* 35: 53–63.
- Saxena S, Brody AL, Schwartz J, Baxter LR (1998). Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. *Br J Psychiatry* 173 (Suppl 35): 26–37.
- Stewart SE, Mayerfeld C, Arnold PD, et al. (2013). Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene SLC1A1. *Am J Med Genet B Neuropsychiatr Genet* 162B(4): 367–379.
- Taylor S (2012). Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. *Mol Psychiatry* 17(7): 799–805.
- Taylor S, Abramowitz JS, McKay D, et al. (2006). Do dysfunctional beliefs play a role in all types of obsessive-compulsive disorder? *J Anxiety Disord* 20(1): 85–97.

**13.5 DIFFERENZIALDIAGNOSTISCHER PROZESS**

- Meier SM, Petersen L, Pedersen MG, et al. (2014). Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study. *JAMA Psychiatry* 71(11): 1215–1221.
- Rasmussen SA, Eisen JL (1992). Epidemiologie und Differentialdiagnose der Zwangsstörung. In: Hand I, Goodman WK, Evers U (Hrsg.). *Zwangsstörungen. Neue Forschungsergebnisse*. Berlin, Heidelberg, New York: Springer, S. 1–14.

**13.6 THERAPIE**

- Albert U, Marazziti D, Di Salvo G, et al. (2017). A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. *Curr Med Chem* Dec 22; doi: 10.2174/0929867325666171222163645 [Epub ahead of print].
- Baer L (2007). *Der Kobold im Kopf*. Bern, Göttingen, Toronto, Seattle: Huber.
- Fisher PL, Wells A (2005). How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. *Behav Res Ther* 43: 1543–1558.
- Hoffmann N, Hofmann B (2013). *Wenn Zwänge das Leben einengen – der Klassiker für Betroffene*. Berlin, Heidelberg: Springer.
- Kordon A, Kahl KG, Brooks A, et al. (2005). Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. *Eur Arch Psychiatry Clin Neurosci* 255(1): 48–50.
- Salkovskis PM, Ertle A, Kirk J (2009). Zwangsstörung In: Margraf J (Hrsg.). *Lehrbuch der Verhaltenstherapie*. 3. überarb. A. Berlin: Springer, S. 66–86.
- Skapinakis P, Caldwell DM, Hollingworth W, et al. (2016). Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 3(8): 730–739.
- Trevizol AP, Shiozawa P, Cook IA, et al. (2016). transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis. *J ECT* 32(4): 262–266.
- Veale D, Miles S, Smallcombe N, et al. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. *BMC Psychiatry* 29(14): 317.
- Wilhelm S, Steketee GS (2006). *Cognitive Therapy for Obsessive-Compulsive Disorder*. Oakland, CA: New Harbinger.

#### LEITLINIEN

DGPPN „S3-Leitlinie Zwangsstörungen“, Version 21.5. 2013, verfügbar unter [www.dgppn.de/publikationen/leitlinien/leitlinien1.html](http://www.dgppn.de/publikationen/leitlinien/leitlinien1.html) oder [www.awmf.org/leitlinien/detail/II/038-017.html](http://www.awmf.org/leitlinien/detail/II/038-017.html) (letzter Zugriff: 9.5.2018).

#### SYSTEMATISCHE COCHRANE-REVIEWS ([WWW.COCHRANE.DE/DEUTSCH](http://WWW.COCHRANE.DE/DEUTSCH))

Gava I, Barbu C, Aguglia E, et al. (2007). Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2: CD005333.  
Ipser JC, Carey P, Dhansay Y, et al. (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 4: CD005473.

Martin JL, Barbanoj MJ, Perez V, Sacristan M (2003). Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder. Cochrane Database Syst Rev 3: CD003387.  
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 1: CD001765.

#### PATIENTENRATGEBER

Hofmann N, Hofmann B (2013). Wenn Zwänge das Leben einengen. 14. A. Berlin, Heidelberg: Springer.  
Külz A (2017). Dem inneren Drachen mit Achtsamkeit begegnen. Selbsthilfe bei Zwängen. Weinheim, Basel: Beltz.  
Reinecker H (2016). Ratgeber Zwangsstörungen – Informationen für Betroffene und Angehörige. 2. A. Bern, Göttingen, Toronto, Seattle: Hogrefe.